United Therapeutics Corporation (UTHR)Healthcare | Drug Manufacturers - Specialty & Generic | Silver Spring, United States | NasdaqGS
588.38 USD
+7.87
(1.356%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 588.50 +0.12 (0.020%) ⇧ (April 17, 2026, 7:10 p.m. EDT) Short-term: ★★★☆☆ | Long-term: ★★★★★ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 10:19 p.m. EDT
Despite severe near-term headwinds from insider selling by the CEO and CFO (millions of dollars sold), UTHR remains a '5-star' long-term buy anchored by exceptional fundamentals: 41.9% margins, 20.9% earnings growth, and a pristine balance sheet (Debt/Equity 0.53). The aggressive options buying at current prices is the market way of pricing in a recovery; for long-term investors, the insider dump is a temporary distraction, and the company is an obvious cornerstone holding for healthcare portfolios. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.088402 |
| AutoARIMA | 0.090306 |
| AutoETS | 0.090306 |
| MSTL | 0.093223 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 382.51 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.143 |
| Excess Kurtosis | -1.42 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.53 |
| Revenue per Share | 71.844 |
| Market Cap | 25,787,334,656 |
| Trailing P/E | 21.10 |
| Forward P/E | 17.28 |
| Beta | 0.75 |
| Profit Margins | 41.94% |
| Website | https://www.unither.com |
As of April 18, 2026, 10:19 p.m. EDT: Options flow indicates strong bullish positioning for the medium term (June-Aug 2026), with significant Out-of-the-Money (OTM) Call volume and Open Interest concentrated at the 600-660 strikes. Crucially, ATM CalloI dominates (ratio > 0.9), while short-term puts show near-total hedging (ITM OI negligible). While IV is low (~41%), a notable volume spike exists at the 620-650 strikes, suggesting speculators are pricing in a move toward the 600-660 resistance zone within 2-3 months.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.0699384 |
| Address1 | 1,000 Spring Street |
| All Time High | 607.89 |
| All Time Low | 4.275 |
| Ask | 588.16 |
| Ask Size | 1 |
| Audit Risk | 3 |
| Average Analyst Rating | 1.7 - Buy |
| Average Daily Volume10 Day | 523,790 |
| Average Daily Volume3 Month | 519,601 |
| Average Volume | 519,601 |
| Average Volume10Days | 523,790 |
| Beta | 0.75 |
| Bid | 588.0 |
| Bid Size | 3 |
| Board Risk | 5 |
| Book Value | 162.596 |
| City | Silver Spring |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 4 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 588.38 |
| Current Ratio | 6.605 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 592.48 |
| Day Low | 574.59 |
| Debt To Equity | 0.53 |
| Display Name | United Therapeutics |
| Earnings Call Timestamp End | 1,772,028,000 |
| Earnings Call Timestamp Start | 1,772,028,000 |
| Earnings Growth | 0.245 |
| Earnings Quarterly Growth | 0.209 |
| Earnings Timestamp | 1,772,026,200 |
| Earnings Timestamp End | 1,777,465,800 |
| Earnings Timestamp Start | 1,777,465,800 |
| Ebitda | 1,602,700,032 |
| Ebitda Margins | 0.50356996 |
| Enterprise To Ebitda | 14.291 |
| Enterprise To Revenue | 7.197 |
| Enterprise Value | 22,904,633,344 |
| Eps Current Year | 28.8375 |
| Eps Forward | 34.04667 |
| Eps Trailing Twelve Months | 27.88 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 525.2458 |
| Fifty Day Average Change | 63.134216 |
| Fifty Day Average Change Percent | 0.120199375 |
| Fifty Two Week Change Percent | 106.99384 |
| Fifty Two Week High | 607.89 |
| Fifty Two Week High Change | -19.51001 |
| Fifty Two Week High Change Percent | -0.03209464 |
| Fifty Two Week Low | 272.12 |
| Fifty Two Week Low Change | 316.26 |
| Fifty Two Week Low Change Percent | 1.162208 |
| Fifty Two Week Range | 272.12 - 607.89 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 929,626,200,000 |
| Float Shares | 40,316,650 |
| Forward Eps | 34.04667 |
| Forward P E | 17.281572 |
| Free Cashflow | 583,200,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 1,400 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.87921995 |
| Gross Profits | 2,798,299,904 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01941 |
| Held Percent Institutions | 0.976 |
| Implied Shares Outstanding | 43,827,686 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,253,664,000 |
| Last Split Factor | 2:1 |
| Long Business Summary | United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland. |
| Long Name | United Therapeutics Corporation |
| Market | us_market |
| Market Cap | 25,787,334,656 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_36018 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | 1,334,700,032 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 25,779,883,182 |
| Number Of Analyst Opinions | 13 |
| Open | 580.51 |
| Operating Cashflow | 1,561,200,000 |
| Operating Margins | 0.45229 |
| Overall Risk | 2 |
| Payout Ratio | 0.0 |
| Peg Ratio | 2.31 |
| Phone | 301 608 9292 |
| Post Market Change | 0.11999512 |
| Post Market Change Percent | 0.020394152 |
| Post Market Price | 588.5 |
| Post Market Time | 1,776,467,406 |
| Previous Close | 580.51 |
| Price Eps Current Year | 20.403296 |
| Price Hint | 2 |
| Price To Book | 3.6186624 |
| Price To Sales Trailing12 Months | 8.102345 |
| Profit Margins | 0.41936 |
| Quick Ratio | 5.834 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.66667 |
| Region | US |
| Regular Market Change | 7.87 |
| Regular Market Change Percent | 1.3557 |
| Regular Market Day High | 592.48 |
| Regular Market Day Low | 574.59 |
| Regular Market Day Range | 574.59 - 592.48 |
| Regular Market Open | 580.51 |
| Regular Market Previous Close | 580.51 |
| Regular Market Price | 588.38 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 662,752 |
| Return On Assets | 0.1244 |
| Return On Equity | 0.19715 |
| Revenue Growth | 0.074 |
| Revenue Per Share | 71.844 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 1 |
| Shares Outstanding | 43,827,686 |
| Shares Percent Shares Out | 0.0647 |
| Shares Short | 2,837,307 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 1,732,175 |
| Short Name | United Therapeutics Corporation |
| Short Percent Of Float | 0.0858 |
| Short Ratio | 4.4 |
| Source Interval | 15 |
| State | MD |
| Symbol | UTHR |
| Target High Price | 733.0 |
| Target Low Price | 519.0 |
| Target Mean Price | 644.0769 |
| Target Median Price | 660.0 |
| Total Cash | 2,920,300,032 |
| Total Cash Per Share | 66.631 |
| Total Debt | 37,600,000 |
| Total Revenue | 3,182,700,032 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 27.88 |
| Trailing P E | 21.104017 |
| Trailing Peg Ratio | 2.3441 |
| Triggerable | 1 |
| Two Hundred Day Average | 441.53864 |
| Two Hundred Day Average Change | 146.84137 |
| Two Hundred Day Average Change Percent | 0.33256742 |
| Type Disp | Equity |
| Volume | 662,752 |
| Website | https://www.unither.com |
| Zip | 20,910 |